Top News arrow News / Infomails
News and Infomails from AHRP
UK-MHRA Drug-Related Suicide Reports_Yellow Card Print E-mail
Wednesday, 01 March 2006
The UK adverse event drug reporting system utilizes the Yellow Card system for filing reports.
Read more...
 
Glaxo to Polish Industry Image Print E-mail
Wednesday, 01 March 2006
AdAge reports:

GLAXO DRAFTS EMPLOYEES TO POLISH INDUSTRY IMAGE
Read more...
 
Comparison of Suicide Rates in Treated Schizophrenia Patients Found 20-Fold Increase Print E-mail
Wednesday, 01 March 2006

An analysis published in the current issue of the British J of Psychiatry (BJP)  of the suicide rate among schizophrenia patients treated at the same hospital in North Wales (UK) before psychotropic drugs and patients treated (in and out of hospital) with neuroleptics and /or atypical antipsychotics, found a 20-fold increase in the suicide rate since use of psychotropic drugs. 

Read more...
 
Despite Undisclosed Deaths, 10 Heart Attacks FDA Allows Blood Substitute Experiment With No Conset Print E-mail
Monday, 27 February 2006
The Wall Street Journal reports: “The FDA is allowing Northfield [Laboratories, Inc] to test its blood substitute without the consent of the trauma patients, who often are unconscious.”
Read more...
 
More...
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Results 617 - 630 of 753
[ Back ]
(C) 2012 Alliance for Human Research Protection
CMS installation and website development by Anne Krauss

General Terms & Disclaimer:

This site is not a monologue of truth. It is a catalyst for public debate about medical research conduct. The reader is urged to confront officials to clarify issues mentioned herein. This site is designed strictly to provide information for critical, literary, academic an public usage. A qualified and trustworthy medical professional must be consulted regarding medical issues, treatments, diagnoses, etc.

Please read the General Terms and Conditions of this agreement entirely and carefully before accessing this web site. By accessing the site, you agree to be bound by the terms and conditions listed herein. [continue]